NT-proBNP-guided assessment reduced costs by US$1002.73 and increased QALYs by 0.055 compared to usual care in patients with T2DM in China.
Does NT-proBNP-guided heart failure risk assessment improve health outcomes and reduce costs compared to usual care in patients with T2DM in China?
NT-proBNP-guided HF risk assessment is a cost-saving strategy for patients with T2DM in China, reducing both HF cases and healthcare costs.
Absolute Event Rate: 0% vs 0%
AIMS: Heart failure (HF) affects up to 40 % of patients with type 2 diabetes mellitus (T2DM), imposing significant clinical and economic burdens. N-terminal pro-B-type natriuretic peptide (NT-proBNP) effectively assesses HF risk, but its economic value in China is unclear. METHODS: This study evaluated the cost-effectiveness of three HF risk assessment strategies in patients with T2DM: NT-proBNP-guided assessment (using a cut-off of ≥125 pg/mL), usual care in China, and Systematic COronary Risk Evaluation (SCORE). A decision tree and Markov model with 1-year cycles simulated lifetime direct medical costs (given in United States dollars US) and health outcomes in patients with T2DM aged ≥40 years from a Chinese healthcare perspective. High-risk patients received SGLT2 inhibitors plus standard of care. RESULTS: Compared with usual care, the NT-proBNP-guided strategy was cost-saving, reducing costs by US1002. 73 while increasing QALYs by 0. 055 per patient. It was also less costly and more effective than the SCORE strategy. Probabilistic sensitivity analysis confirmed the robustness of this finding, demonstrating a 96. 9 % probability of the NT-proBNP strategy being cost-saving versus usual care. CONCLUSIONS: NT-proBNP is a dominant and robust cost-saving strategy for HF risk assessment in patients with T2DM in China, reducing both HF cases and associated healthcare costs.
Yu et al. (Mon,) reported a other. NT-proBNP-guided assessment reduced costs by US$1002.73 and increased QALYs by 0.055 compared to usual care in patients with T2DM in China.